Angiotensin II (Ang II) interaction with the neuronal AT 1 receptor results in a chronic stimulation of neuromodulation that involves the expression of norepinephrine transporter (NET) and tyrosine hydroxylase (TH). In view of this unique property and the presence of putative nuclear localization signal (NLS) consensus sequence in the AT 1 receptor, this study was conducted to investigate the hypothesis that Ang II would induce nuclear sequestration of this G proteincoupled receptor and that the sequestration may have implications on Ang II-induced expression of NET and TH genes. Incubation of neuronal cultures with Ang II caused a time-and dose-dependent increase in the levels of AT 1 receptor immunoreactivity in the nucleus. A 6.7-fold increase was observed with 100 nM Ang II, in 15 min, that was blocked by losartan, an AT 1 receptor-specific antagonist. Ang II-induced nuclear sequestration was specific for AT 1 receptor, because Ang II failed to produce a similar effect on neuronal AT 2 receptors. The presence of the putative NLS sequence in the cytoplasmic tail of the AT 1 receptor seems to be the key in nuclear targeting because: 1) nuclear targeting was attenuated by a peptide of the AT 1 receptor that contained the putative NLS sequence; and 2) Ang II failed to cause nuclear translocation of the AT 2 receptor, which does not contain the putative NLS.
receptor that contained the putative NLS sequence; and 2) Ang II failed to cause nuclear translocation of the AT 2 receptor, which does not contain the putative NLS.
Ang II also caused a time-and dose-dependent stimulation of P62 phosphorylation, a glycoprotein of the nuclear pore complex. A 6-fold stimulation of phosphorylation was observed with 100 nM Ang II, in 15 min, that was completely blocked by losartan and not by PD123,319, an AT 2 receptor specific antagonist. Preloading of neurons with p62-pep (a peptide containing consenses of mitogen-activated protein kinase in p62) resulted in a loss of Ang II-induced p62 phosphorylation and stimulation of NET and TH messenger RNA levels.
In conclusion, these data demonstrate that Ang II induces nuclear sequestration of AT 1 receptor involving NLS in the AT 1 receptor and p62 of the nuclear pore complex in brain neurons. A possible role of such a nuclear targeting of the AT 1 receptor on chronic neuromodulatory actions of Ang II has been discussed. (Endocrinology 139: [365] [366] [367] [368] [369] [370] [371] [372] [373] [374] [375] 1998) A NGIOTENSIN II (Ang II) interacts with the neuronal AT 1 receptor and stimulates its chronic neuromodulatory actions involving the expression of norepinephrine transporter (NET), tyrosine hydroxylase (TH), and dopamine ␤ hydroxylase genes (1, 2) . These actions of the AT 1 receptor have been linked to the central control of blood pressure by Ang II (3, 4) . AT 1 receptor belongs to the Gprotein-coupled receptor (GPCR) superfamily that contains seven transmembrane regions (5) (6) . The receptor is linked to the Gq subtype of G protein and is coupled to inositol phosphate and protein kinase C signal transduction pathway (7, 8) . Other studies have indicated that the AT 1 receptor is also coupled to many other signaling kinases, including Ras, Raf-1, mitogen-activated protein kinase (MAP kinase), phospholipase A, Ca 2ϩ -dependent calmodulin protein kinase, Jak-Stat, and jun kinase (9 -11) . In spite of the observations, the precise involvement of these signaling molecules in diverse cellular and physiological actions of Ang II is not well understood.
We have focused our efforts to elucidate the signal transduction pathways involved in the chronic Ang II-induced neuromodulation. Our studies have established that the interaction of Ang II with the neuronal AT 1 receptor initiates a cascade of signaling events involving the activation of Ras, Raf-1, and MAP kinase (9) . Activation of MAP kinase leads to increased activities of serum response element and AP1-binding elements that result in the increased transcription of NET, dopamine ␤ hydroxylase, and TH genes (12) . Thus, it is evident, from the above discussion, that the neuronal AT 1 receptor is a unique GPCR: 1) it is linked to Ras, Raf-1, and MAP kinase signal transduction pathways involved in the chronic neuromodulatory actions of Ang II; and 2) desensitization and down-regulation of AT 1 receptor, induced by Ang II, does not seem to have an effect on chronic stimulation of neuromodulation (13) . This is, in contrast to other GPCRs, where agonist-induced cellular responses are immediately followed by desensitization and down-regulation of the receptor (14) . Thus, we hypothesized that a distinct Ang II-induced intracellular targeting of the neuronal AT 1 receptor could account for the uniqueness. This view is supported by the sequence analysis of the AT 1 receptor, which indicates the presence of a sequence of basic amino acids in the cytoplasmic tail (KKFKK, amino acids 307-311 ), which could possibly form a nuclear localization signal (NLS) sequence. NLS sequences are involved in the nuclear transport of various signaling proteins that exert transcriptional control by their sequestration into the nucleus (15, 16) . Thus, our objective in this investigation was to test the hypothesis that Ang II induces translocation of AT 1 receptor into the nuclear compartment in the neurons and to determine the involvement of NLS in this targeting.
The data demonstrate that, indeed, the AT 1 receptor is targeted to the nucleus, and we present evidence that the putative NLS sequence and phosphorylation of p62, a protein of the nuclear pore complex (NPC), are important in this targeting.
Materials and Methods
One-day-old Wistar Kyoto rats were obtained from our breeding colony, which originated from Harlan Sprague-Dawley (Indianapolis, IN). DMEM, plasma-derived horse serum (PDHS), and trypsin (150 U/mg) were from Central Biomedia (Irwin, MD (17) (18) (19) (20) (21) (22) (23) . AT 2 receptor-specific antibody was a gift from Dr. Steven Fluharty, University of Pennsylvania, Philadelphia, PA. Specificity of this antibody has been established previously (24) . Rabbit anti-p62 antibody was obtained from Dr. John Hanover, NIH, Bethesda, MD. Its ability to specifically recognize p62 of the NPC has been discussed elsewhere (25) . Protein A/G PLUS-agarose was purchased from Santa Cruz Biotechnology. Genemed Biotechnologies, Inc. (San Francisco, CA) provided synthetic peptides used in this study. All other reagents were purchased from Fisher Scientific (Pittsburgh, PA) and were of the highest quality available.
Preparation of neuronal cells in primary culture
Neuronal cells in primary culture were established essentially as described previously (26, 27) . Briefly, areas containing hypothalamus and brain stem of 1-day-old Wistar Kyoto normotensive rat brains were dissected, brain cells dissociated by trypsin, and plated in poly l-lysine precoated tissue culture dishes in DMEM containing 10% PDHS (26, 27) . Culture dishes of 35-mm diameter (3 ϫ 10 6 cells) or 100-mm diameter (2 ϫ 10 7 cells) were prepared for experiments. After 48 h, cultures were treated with 1% cytosine arabinoside for 3 days, followed by establishment of culture for an additional 10 days, before their use in experiments. These cultures contain 90 -95% neuronal cells and 5-10% astroglial cells (4, 26, 27) .
Immunofluorescent staining of neurons for AT 1 and AT 2 receptors
Neuronal cells were fixed in 1% buffered-formalin. In certain experiments, nuclei from neuronal cells were isolated (see below), fixed onto glass slides in 1% buffered-formalin. Cells or nuclei were treated with methanol for 5 min at Ϫ10 C and preincubated with 10% FBS for 1 h at 37 C. This was followed by incubation with mouse monoclonal anti-AT 1 receptor antibody at 1 g/ml in PBS containing 0.5% BSA for 16 h at 4 C. Rhodamine-conjugated antimouse IgG was used as the second antibody, followed by counterstaining with 4Ј-6-diamidine-2-phenylindole-dihydrochloride (DAPI) to identify nuclear DNA and nuclei, as described previously (12, 13) . Appropriate controls, in which either primary antibody was replaced by growth medium, without AT 1 receptor antibody or without secondary antibody, were run in parallel to determine nonspecific staining. Use of polyclonal AT 1 receptor antibody provided a similar staining pattern, although the monoclonal antibody provided a picture with lower background. The cells were processed for confocal microscopy, as described previously (1) . Distribution of AT 2 receptor immunoreactivity was determined as described above for the AT 1 receptor, except that a polyclonal AT 2 receptor-specific antibody and rhodamine-conjugated antirabbit second antibody were used. The specificity of this antibody has previously been established (25) .
Isolation of nuclei and immunoblotting of AT 1 receptors from neuronal cells
Neuronal cells, grown in 100-mm-diameter tissue culture dishes, were used to separate nuclear fraction from the rest of the cell fraction, as described by us elsewhere (12) (13) . This protocol yields highly pure nuclear fraction that was minimally contaminated by cytoplasmic marker proteins (12) (13) . Purified nuclei were lysed in the nuclear lysis buffer (25 mm Tris-HCl, pH 7.4, 25 mm NaCl, 1% Triton ϫ 100, 1% deoxycholic acid, 0.1% SDS, 1 mm sodium orthovanadate, 1 mm phenylemethylsulfonyl fluoride, 10 g/ml aprotinin, and 0.8 g/ml leupeptin). Lysate was centrifuged at 12,000 ϫ g for 5 min at 4 C, and the supernatant was saved as nuclear extract for AT 1 receptor immunoblotting.
Extract containing 400 g protein was mixed with 1 g rabbit anti-AT 1 receptor polyclonal antibody overnight at 4 C. Immunoprecipitates were collected on protein A/G agarose and subjected to SDS-PAGE, followed by immunoblotting with the use of AT 1 receptor monoclonal antibody, as described elsewhere (13) . Although both antibodies, on their own, provided similar results, this combination use of polyclonal (for immunoprecipitation) and monoclonal (for immunoblotting) AT 1 receptor antibodies provided highly specific AT 1 receptor bands with very little background. Protein-bound antibody was detected by HRP-labeled second antibody and enhanced by a chemiluminescence assay reagent. Bands corresponding to the AT 1 receptor (ϳ49 kDa protein) were visualized by exposure to x-ray film. X-ray films were scanned by using a UVP Imagestore 5000 System (UV Product, San Gabriel, CA). Data were analyzed using a SW 5000 Gel Analysis program and presented as observed density in the AT 1 receptor band that was normalized for equal loading by total protein, as described previously (9, 12) . In certain experiments, neuronal cells and nuclear extracts were subjected to SDS-PAGE, proteins transferred to membrane that was subjected to Western blotting with the use of either polyclonal or monoclonal AT 1 receptor antibody, essentially as described previously (28) .
Osmotic loading of synthetic peptides into neurons
A peptide corresponding to the AT 1 receptor tail [amino acids 295- 315, LNPLFYGFLGKKFKKYFLALL (AT 1 -pep)] and its mutant, in which lysine residues at amino acids 305, 306, 308, 309 were replaced by alanine (AT 1 -mut), were synthesized. The rationale for selecting this sequence was based on the identification of a putative NLS sequence (amino acids [307] [308] [309] [310] [311] ) in this region of the receptor. Another peptide corresponding to amino acids 189 -198 of p62 [GSPFTPATLA (p62-pep)] and its mutant, in which Thr 193 was replaced by Ala (p62-mut), were synthesized. All peptides were synthesized by Genemed Biotechnologies Inc. This region contained the consensus recognition sequence FIG. 1. Western blot analysis of neuronal AT 1 receptor by polyclonal and monoclonal AT 1 receptor-specific antibodies. Neuronal cultures were treated with 100 nM Ang II for 15 min at 37 C. Whole-cell (W) extracts and nuclear (N) extracts, containing 100 g protein from Ang II-treated neurons, were subjected to Western blot analysis, essentially as described elsewhere (28) . A, Polyclonal antibody; B, monoclonal antibody; C, immmunoprecipitation with the polyclonal antibody, followed by immunoblotting by monoclonal antibody (from Dr. Vinson).
for MAP kinase phosphorylation (29) . The reason for selecting this region of the p62 was based on our previous observation that Ang II stimulates MAP kinase and that MAP kinase is involved in chronic neuromodulatory actions of Ang II (9, 12) . Osmotic loading of these peptides was carried out essentially as described previously (30) . In brief, neuronal cells were rinsed in PBS, pH 7.4, incubated for 10 min with loading solution (0.5 m sucrose, 10% polyethylene glycol 1000, 10% FBS, and 200 g/ml AT 1 -pep or p62pep or their mutants in DMEM, buffered with 25 mm HEPES, pH 6. 
Effect of Ang II on phosphorylation of neuronal p62 protein
Neuronal cells were grown in 100-mm-diameter tissue culture dishes. They were rinsed in phosphate-free DMEM and were incubated with 20 mCi [
32 P]-orthophosphate in phosphate-free DMEM for 2 h at 37 C. After incubation with 100 nm Ang II at 37 C, cells were rinsed six times with ice-cold PBS, pH 7.4, and lysed for 20 min on ice in the lysis buffer (25 mm Tris-HCl, pH 7.4, 25 mm NaCl, 1% Triton X-100, 1% deoxycholic acid, 1 mm sodium orthovanadate, 10 mm sodium fluoride, 10 mm sodium pyrophosphate, 0.5 mm EGTA, 1 mm phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 0.8 g/ml leupeptin). Samples were centrifuged at 12,000 g for 5 min at 4 C, and supernatants containing 200 g protein were used for immunoprecipitation by anti-p62 (5 g) spe-
FIG. 2. Immunofluorescent
localization of AT 1 receptor immunoreactivity in neuronal cells by polyclonal and monoclonal AT 1 receptor-specific antibodies. Neuronal cells were fixed and subjected to immunofluorescent staining with the use of 2.5 g/ml polyclonal antibody (C) or 1 g/ml monoclonal antibody (D), essentially as described in Materials and Methods. Controls in which primary antibodies were replaced with normal rabbit serum (A) or PBS (B) also were prepared. Cells were processed for confocal microscopy. Data are representative of examination of approximately 200 cells. PC12 cells were established to predominantly express AT 2 receptors, essentially as described elsewhere (31) (32) . They were incubated with polyclonal (E) or monoclonal (F) antibodies and analyzed by confocal microscopy similar to that described for neuronal cells. cific antibody. Immune complexes were collected on agarose beads, conjugated with protein AϩG (Santa Cruz Biotechnology), suspended in Laemmli's sample buffer, boiled for 3 min, and subjected to SDS/ PAGE, followed by autoradiography (9, 12) . The radiolabeled band corresponding to a 62,000 MW protein was quantitated essentially as described previously (12, 13) .
Quantitation of NET and TH messenger RNAs (mRNAs) by RT-PCR
Neuronal cells were osmotically loaded with p62-pep or p62-mut and stimulated with Ang II for 4 h. Total RNA was isolated, and NET and TH mRNA levels were quantitated by a semiquantitative RT-PCR, essentially as described previously (1, 2) .
Experimental groups and data analysis
Each data point for the measurement of nuclear AT 1 receptor immunoreactivity, p62 phosphorylation, and NET and TH mRNAs was collected from three culture dishes. Each culture dish contained cells generated by pooling of dissociated brain cells from 8 -10 rats. Each data point was repeated at least 3 times. Comparisons between data points were made by using one-way ANOVA and Dunnett's test, using Statistica Software (Tulsa, OK). All immunofluorescence experiments were repeated at least 6 times. One hundred to 250 cells were examined, and representative images were collected.
Results

Characterization of polyclonal and monoclonal AT 1 receptor antibodies
Western blot analysis of neuronal proteins, with the use of rabbit anti-AT 1 receptor polyclonal antibody, provided a predominant protein band corresponding to approximately 49 kDa, similar to that observed previously (13) . A minor protein band of approximately 60 kDa was also observed. Nuclear fraction prepared from 100 nm Ang II-treated neurons also showed a predominant (ϳ49 kDa) and a minor (ϳ60 kDa) protein bands (Fig. 1) . Western blot analysis of control neurons and nuclear extracts of Ang II-treated neurons, with the use of monoclonal antibody, provided identical results (Fig. 1) . This indicated that both monoclonal and polyclonal antibodies, raised against AT 1 receptor, recognize protein of approximately 49 kDa as a major AT 1 receptor protein in neuronal cells. Specificity of these antibodies was further confirmed in control Western blotting, in which PBS or normal rabbit serum were substituted for primary antibodies. No protein band of approximately 49 kDa was observed in these controls. Neuronal cell extract or nuclear extract from Ang II-treated cells was subjected to immunoprecipitation with polyclonal AT 1 receptor antibody, followed by immunoblotting with monoclonal antibody, essentially as described in Materials and Methods. This protocol also provided a predominant protein band of approximately 49 kDa, with a minor band of approximately 60 kDa, similar to that seen with the individual antibodies on Western blots (Fig. 1C) . These data showed that both antibodies recognize the same AT 1 receptor protein in neuronal cells and in the nuclear fraction of Ang II-treated neurons. These data are consistent with, at least, the observations reported with the monoclonal AT 1 receptor antibody. They show that this antibody recognizes AT 1 receptor protein of varying size (44 -70 kDa), indicating that the SDS-PAGE mobility of the receptor may be tissue specific (17) (18) (19) (20) (21) (22) (23) .
Further characterization of both AT 1 receptor antibodies was carried out by immunofluorescence, followed by confocal microscopy. Figure 2 shows that the distribution of AT 1 receptor immunoreactivity in neuronal cells was comparable with both polyclonal (Fig. 2B) and monoclonal (Fig. 2D) antibodies. AT 1 receptor immunoreactivity was predominantly localized in the plasma membrane; however, some staining was detected in the intracellular compartment. Although the staining pattern was comparable with both antibodies, the monoclonal antibody provided significantly lower background. No significant staining was observed when primary antibodies were replaced with normal rabbit serum for polyclonal ( Fig. 2A) , or PBS for monoclonal, antibody (Fig. 2C) . In addition, no staining was seen when fluorescently-labeled secondary antibodies were deleted from the staining protocol. Finally, both antibodies provided little descrete staining for AT 1 receptor immunoreactivity in PC12 cells (Fig. 2, E and F) . This is consistent with other observations indicating that these cells predominantly express AT 2 , and not AT 1 , receptor subtypes (31, 32) . Thus, monoclonal antibody was used for all subsequent immunofluorescent experiments, and a combination of polyclonal for immunoprecipitation, followed by immunoblotting by monoclonal antibodies, was used in quantitation of an AT 1 receptor band of approximately 49 kDa.
Characterization of the effects of Ang II on AT 1 receptor targeting
AT 1 receptor immunoreactivity was predominantly localized on the plasma membrane of neuronal cell soma (Fig.  3A) . Confocal imaging also indicated that a significant AT 1 receptor immunoreactivity was present in the cytoplasmic compartment of the neuronal cells (Fig. 3A) . In contrast, no detectable level of the receptor immunoreactivity was observed in the nuclear compartment. A dramatic redistribution of AT 1 receptors was observed when neurons were incubated with 100 nm Ang II for 15 min. Ang II-treated neurons revealed receptor immunoreactivity, apparently in the nuclei (Fig. 3A) . The nuclear sequestration was time-and dose-dependent and reached maximal levels in 15-30 min with 100 nm Ang II. It was blocked by coincubation of neurons with Ang II and 10 m losartan, an AT 1 receptor subtype-specific antagonist and not by 10 m PD123319, an AT 2 receptor-specific antagonist (Fig. 3A) . Nuclear fractions from the control and Ang II-treated neurons were prepared according to previously established protocol (12, 13) . They were analyzed by immunoblotting to confirm the nuclear sequestration of AT 1 receptor immunoreactivity detected by immunofluorescence technique. Nuclear fractions from control, untreated neurons showed low, but significant, levels of AT 1 receptor immunoreactivity (Fig. 3B) . Ang II caused a 6.7-fold increase in the levels of AT 1 receptor immunoreactivity in the nuclear fraction that was blocked by losartan and not by PD123319 (Fig. 3B) . This indicated that the occupancy of AT 1 receptor by Ang II is important in its nuclear targeting. Ang II caused a time-dependent increase in the nuclear sequestration of this immunoreactivity. It was 3-fold in 5 min and reached optimal levels (6-fold) in 15 min, followed by a 15% decrease in 30 min (Fig. 4) . Increases in AT 1 receptor immunoreactivity in the nuclear fraction were associated with its parallel decrease in the rest of the cell fractions (Fig.  4) . Nuclear sequestration of AT 1 receptor immunoreactivity also was Ang II concentration-dependent. Ang II as low as 10 nm showed a 3-fold increase, whereas 100 nm caused a maximal (4-fold) increase in nuclear immunoreactivity (Fig. 5) .
Neuronal cultures express functional AT 2 subtype of Ang II receptors. It, like AT 1 receptors, belongs to the G protein-coupled receptor (GPCR) superfamily and possess limited homology with the AT 1 receptor (33) (34) . The effect of Ang II on the neuronal AT 2 receptor distribution was studied to determine the specificity of AT 1 receptor nuclear translocation. Figure 6 shows that AT 2 receptor immunoreactivity was primarily localized on neuronal plasma membrane. No significant amount of immunoreactivity was visible in either the cytoplasmic or the nuclear compartments. Incubation with 100 nm Ang II for 30 min caused no significant redistribution of AT 2 receptor immunoreactivity on the plasma membrane. In addition, no nuclear translocation and sequestration of the AT 2 receptor immunoreactivity was observed.
Role of putative NLS and p62 in Ang II-induced nuclear sequestration of the AT 1 receptor
Our next objective was to determine the role of the putative NLS sequence, present in the AT 1 receptor, on nuclear translocation of AT 1 receptor. Neuronal cultures were preloaded with the AT 1 -pep or AT 1 -mut, followed by stimulation with Ang II and immunoblotting of nuclear fractions for AT 1 receptor immunoreactivity. Figure 7A shows that preincubation of neurons with the AT 1 -pep caused an 85% decrease in the AT 1 receptor immunoreactivity in the nuclear fraction. AT 1 -mut had no effect on this nuclear targeting. Figure 7B confirms these observations with the use of confocal microscopy of nuclear preparations. Ang II-induced nuclear sequestration (Fig. 7B ) was attenuated by AT 1 -pep and not by AT 1 -mut. Nuclei from control neurons or neurons treated with AT 1 -pep or with AT 1 -mut showed very little AT 1 receptor immunoreactivity.
It is well established that the NPC plays an important role in the transport of cytoplasmic proteins across the nuclear membrane and their sequestration into the nucleus (35, 36) . NPC is an intricate organization of specific proteins and macromolecules whose activity may be regulated by phosphorylation events (35) . p62 is a protein of the NPC which contains many potential phosphorylation sites for kinases, including MAP kinase (29) . Thus, it could be an important target for phosphorylation-mediated regulation of the NPC activity. Based on this, and our observations that Ang II stimulates MAP kinase (9, 12), we hypothesized that p62 phosphorylation may be important in Ang II-induced nuclear targeting of the AT 1 receptor. Thus, we studied the effects of Ang II on p62 phosphorylation and involvement of this phosphorylation in the nuclear sequestrating of the AT 1 receptor. Figure 8 shows that Ang II caused a time-dependent increase in the incorporation of [ 32 P]-orthophosphate into p62. A 2-fold increase in the phosphorylation, observed as early as 5 min, reached a maximal level of 6-fold in 15 min, followed by a slight decline in 30 min. Interestingly, the time course of p62 phosphorylation was similar to that observed for nuclear sequestration of the AT 1 receptor. Figure 9 shows that Ang II-induced p62 phosphorylation was blocked by losartan and not by PD123319, indicating the involvement of the AT 1 receptor in this process. FIG. 6 . Effect of Ang II on neuronal AT 2 receptor distribution. Neuronal cultures were incubated without (control) or with 100 nM Ang II for 15 min at 37 C, essentially as described in Fig. 1 . This was followed by immunofluorescence analysis with AT 2 receptor antibodies and confocal microscopy, as described in Materials and Methods.
Neuronal cultures were preloaded with p62-pep to determine its effects on Ang II-induced nuclear sequestration of the AT 1 receptor. We have established that p62-pep completely blocks Ang II-induced phosphorylation of p62, whereas it has no effect on Ang II-induced phosphorylation of AT 1 receptor or Stat3. Figure 10A shows that the nuclei isolated from neurons preloaded with p62-pep before Ang II treatment, had little AT 1 receptor immunoreactivity. In contrast, nuclei from neurons preloaded with p62-mut showed levels of AT 1 receptor immunoreactivity comparable with the Ang II-treated neurons. This indicated that Ang II stimulates phosphorylation of p62 and that inhibition of p62 phosphorylation causes attenuation of Ang II-induced nuclear translocation of AT 1 receptors. Figure 10B provides confocal microscopic evidence of this observation. Preloading of p62-pep resulted in a significant decrease in AT 1 receptor immunofluorescence in the nuclei of Ang II-treated neurons. p62-mut showed no such inhibitory action.
Finally, we studied the role of p62 phosphorylation and nuclear sequestration of the AT 1 receptor in effecting Ang II's cellular actions. The effects of Ang II on NET and TH mRNA levels were studied. We hypothesized that if p62 phosphorylation is important in chronic neuromodulation, then Ang II stimulation of NET and TH mRNA levels would be inhibited by blocking the phosphorylation of p62. The data in Fig. 11 , indeed, illustrate this point. Preloading of p62-pep, after Ang II stimulation, resulted in a 70% decrease in Ang II stimulation of NET and TH mRNA levels. p62-mut had no such inhibitory effect. It is pertinent to point out that the FIG. 7. The effect of AT 1 -pep on Ang II-induced nuclear targeting of the AT 1 receptor in neurons. A, Immunoblotting: Neuronal cells were loaded without or with AT 1 -pep or its mutant analog, AT 1 -mut. This was followed by incubation with 100 nM Ang II for 15 min at 37 C. Nuclei were isolated, and AT 1 receptor immunoblotting was carried out as described in Materials and Methods. Top, A representative autoradiogram; bottom, quantitation of bands corresponding to the AT 1 receptor, as described in Materials and Methods. Data are mean Ϯ SE (n ϭ 3). *, Significantly different (P Ͻ 0.05) from control; **, significantly different (P Ͻ 0.05) from Ang II treatment. B, Immunofluorescence by confocal microscopy: Experimental conditions are identical to those described in 4A. Immunofluorescence for the AT 1 receptor in nuclear fraction was carried out as described in Materials and Methods. Blue represents DAPI staining of nuclear DNA, whereas red represents AT 1 receptor immunostaining.
experimental conditions also inhibit Ang II-induced nuclear sequestration of Stat3 and AT 1 receptors.
Discussion
In this study, we have established that the neuronal AT 1 receptor, a GPCR, is targeted to the nucleus when it is stimulated by Ang II. The molecular basis for this nuclear targeting is consistent with the presence of the NLS in its cytoplasmic tail and involves phosphorylation of p62, an NPC protein. The observations are in accordance with earlier reports in which nuclear Ang II receptors have been demonstrated in hepatocytes (37, 38) . The evidence for nuclear targeting includes the following: 1) Neuronal cells express the AT 2 receptor subtype, which also belongs to the GPCR superfamily, shares a limited homology, and binds Ang II with a comparable affinity with the AT 1 receptor (33) (34) . In spite of these similarities, the AT 2 receptor is distinct from the AT 1 receptor, both physiologically and functionally (7, 39, 40) . In addition, Ang II does not cause nuclear translocation of this receptor under the same experimental conditions that cause nuclear targeting of the AT 1 receptor. 2) AT 1 receptor on astroglial cells is not translocated into the nucleus under the influence of Ang II. This is true, in spite of the presence of high levels of functional AT 1 receptors in astroglial cells that are coupled to stimulation of glucose transporter and plasminogen-activator inhibitor-1 (41, 42) . In addition, Ang II stimulation also does not cause nuclear sequestration of the AT 1 receptor in vascular smooth-muscle cells (Lu et al., unpublished observation) , in spite of its involvement in chronic hypertrophic and hyperplasic actions of Ang II in these cells (43) . 3) Observations derived from two different methodologies (confocal microscopy and immunoprecipitation) provide complementary results in demonstrating the Ang IIinduced nuclear sequestration of the AT 1 receptor. Two distinct antibodies, generated in two separate laboratories, against two different regions of the AT 1 receptor, demonstrate essentially the same observation. The data also show that Ang II-induced nuclear targeting does not seem to involve a major modification in the size of the AT 1 receptor, because the nuclear receptor is comparable with the plasma membrane receptor. 4) We provide evidence that the putative NLS sequence, present in the cytoplasmic tail region of the receptor, plays an important role in its nuclear targeting. This view is based on the observation that the AT 1 -pep competitively blocks Ang II-induced nuclear targeting of the AT 1 receptor. These data could also explain the failure of nuclear translocation of the neuronal AT 2 receptor, which does not contain putative NLS sequence (33) (34) . These data clearly show that the AT 1 receptor becomes associated with the nuclear fraction of appropriately treated neurons. Although the confocal images suggest that the receptor is actually within the nucleus, the resolution of this technique is not high enough to firmly make this conclusion. Therefore, although the data presented, using NLS and p62 peptides, is consistent with the view that the receptor translocates into the nucleus, it is also possible that the receptor associates with the exterior of the nucleus (for example, by binding to the nuclear membrane). Experiments are currently underway to definitively answer this question. Another significant finding in this study is the involvement of p62 in Ang II-induced nuclear targeting of this GPCR. p62 is an important nucleoporin that participates in the functioning of the NPC during the transport of proteins across the nuclear membrane (35) . In spite of a clear involvement of p62 phosphorylation in this targeting, the precise mechanism remains to be elucidated. This study raises a number of issues concerning the functional relevance of the nuclear targeting of the AT 1 receptor in the neurons. These issues are worthy of discussion that will help provide future direction in this field of investigation. First, what are the cellular and physiological consequences of the nuclear targeting of the AT 1 receptor in neurons? We suggest that it may be involved in the chronic neuromodulatory actions of Ang II. This idea is supported by the observation that both nuclear targeting for the AT 1 receptor and the Ang II stimulation of mRNAs for NET and TH are blocked by the inhibition of p62 phosphorylation. Thus, nuclear AT 1 receptors may interact with the DNA, or a specific nuclear protein, to regulate the transcription of NET, TH, or other genes relevant to the neuromodulatory actions of Ang II. There is no evidence in support of this view, because this report is the first example of nuclear targeting of a GPCR. However, analogous situations are well established for steroid hormone receptors. Steroid hormone receptors contain NLS sequences that play an important role in their nuclear translocation. Nuclear targeting is accompanied by specific DNA binding and transcriptional control of various steroidhormone-responsive genes (44 -45) . Second, AT 1 receptors are present, both on the neuronal plasma membrane and in the cytoplasmic compartment, and presently, which compartment contributes to the nuclear AT 1 receptors remains an open question. Binding of Ang II to the plasma membrane FIG. 10 . Effect of p62-pep on Ang II-induced nuclear translocation of neuronal AT 1 receptor. A, Immunoblotting: p62-pep or p62-mut were osmotically loaded in neuronal cells, as described elsewhere (23) . After 100 nM Ang II treatment for 15 min at 37 C, nuclei were isolated and subjected to AT 1 receptor immunoblotting analysis, essentially as described in Materials and Methods. Top, A representative autoradiogram; bottom, a quantitation of 62-kDa bands. Data are mean Ϯ SE (n ϭ 3). *, Significantly different (P Ͻ 0.05) from control; **, significantly different (P Ͻ 0.05) from Ang II-treated cells. B, Immunofluorescence by confocal microscopy: Experimental conditions were identical to those described in the legend to Fig. 7A . Blue represents DAPI staining of nuclear DNA, and red represents AT 1 receptor immunoreactivity.
AT 1 receptor activates the Ras-MAP kinase signal transduction pathway (9) . Activation of MAP kinase results not only in the stimulation of downstream signaling leading to neuromodulation (12) but also in the phosphorylation of the AT 1 receptor (13) . The phosphorylated receptors are internalized (13) . This would suggest that the plasma membrane receptors are translocated into the nucleus. This view is further supported by the observation that both the phosphorylated AT 1 receptor and the nuclear AT 1 receptor lack Ang II binding activity (13) . However, this does not preclude other possibilities of nuclear targeting of cytosolic receptors. Finally, it remains to be determined whether nuclear targeting is specific for the AT 1 receptor or it could be a general phenomenon for other GPCR. It would be surprising that AT 1 receptor was unique in exhibiting agonist-induced nuclear translocation. Indeed, examination of amino acid sequences of other G protein-coupled receptors reveals that several others have sequences in the C-terminal cytoplasmic loop that conform to the consensus expected for the NLS sequence. For example, human M1, M3, and M5A muscarinic acetylcholine receptors contain sequences KRRWRK, KKKRRK, and RWKKKV, respectively (46 -48) . Similarly, the human platelet activating factor receptor contains the sequence KKFRKH, which also might have NLS activity (49) . It remains to be seen whether these receptors, like AT 1 receptor, also translocate to the nucleus after agonist stimulation.
